# Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC

> **NCT07754812** · PHASE4 · RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 78 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** Oral Paclitaxel Solution
- **DRUG:** PD-1/PD-L1 inhibitor
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)
- **PROCEDURE:** Radical Lung Cancer Surgery
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT07754812
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-25
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07754812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07754812, "Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07754812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*